肝纤维化人群筛查:面向慢性肝病的早期诊断与干预
综述指出肝硬化全球高发,主要由非酒精性脂肪性肝病和酒精相关肝病引起,乙型和丙型肝炎在某些地区仍是主要病因。血清学、瞬时弹性成像和影像学可较准确无创评估肝纤维化,可用于高危人群筛查。有限的人群研究显示,一般人群约5%、有危险因素人群18%–27%存在未检出显著肝纤维化或肝硬化,但需更多国际研究评估利弊后再推荐筛查。
要点
- 无创方法可较准确评估肝纤维化,适用于高危人群筛查。
- 一般人群约5%、有危险因素人群18%–27%存在未检出显著肝纤维化或肝硬化。
- 需更多国际研究评估筛查利弊后再决定是否推广人群筛查。
核心结论
- 肝纤维化筛查有望将慢性肝病诊断从肝硬化并发症期提前至无症状肝纤维化阶段,以预防疾病进展。
- 目前证据尚不足以推荐在慢性肝病高危人群中普遍开展肝纤维化筛查,需更多国际研究评估利弊。
研究设计与样本
- 综述总结了肝纤维化无创评估方法及全球有限的人群筛查研究。
主要发现
- 无已知肝病者中,一般人群约5%存在显著未检出肝纤维化或肝硬化。
- 有肝病危险因素人群中,显著未检出肝纤维化或肝硬化比例为18%至27%。
关键数值与推荐
- 血清学试验、瞬时弹性成像和影像学方法可较准确无创评估肝纤维化。
- 肝硬化主要病因为非酒精性脂肪性肝病和酒精相关肝病,部分地区乙型和丙型肝炎仍为主要病因。
临床怎么用
- 可考虑对慢性肝病高危人群采用无创方法筛查肝纤维化,但需权衡利弊并等待更多研究证据。
局限性
- 目前在不同地区开展的非侵入性检测人群研究数量有限。
- 需更大规模国际研究明确筛查的获益与危害。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cirrhosis, highly prevalent worldwide, develops after years of hepatic inflammation triggering progressive fibrosis. Currently, the main etiologies of cirrhosis are non-alcoholic fatty liver disease and alcohol-related liver disease, although chronic hepatitis B and C infections are still major etiological factors in some areas of the world. Recent studies have shown that liver fibrosis can be assessed with relatively high accuracy noninvasively by serological tests, transient elastography, and radiological methods. These modalities may be utilized for screening for liver fibrosis in at-risk populations. Thus far, a limited number of population-based studies using noninvasive tests in different areas of the world indicate that a significant percentage of subjects without known liver disease (around 5% in general populations and a higher rate -18% to 27%-in populations with risk factors for liver disease) have significant undetected liver fibrosis or established cirrhosis. Larger international studies are required to show the harms and benefits before concluding that screening for liver fibrosis should be applied to populations at risk for chronic liver diseases. Screening for liver fibrosis has the potential for changing the current approach from diagnosing chronic liver diseases late when patients have already developed complications of cirrhosis to diagnosing liver fibrosis in asymptomatic subjects providing the opportunity of preventing disease progression.
引用
- Ginès P, Castera L, Lammert F, et al. Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases. Hepatology. 2021. PMID: 34537988. doi:10.1002/hep.32163
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。